Oxbryta Will Be a New Specialty Med for Sickle Cell Disease

March 2020

Oxbryta (oks-BRYE-tuh, voxelotor) will be a new oral tablet to treat sickle cell disease in patients 12 years and older.

Oxbryta may be added to hydroxyurea...which is often used first for sickle cell patients to reduce pain crises, hospitalizations, and possibly improve survival.

But don't expect to stock Oxbryta. It's a specialty Rx...and costs about $10,000/month.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote